Home  /  Resource Library  /  Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter’s transformation: results from the phase II GIVeRS trial

Fixed-duration obinutuzumab-ibrutinib-venetoclax for Richter’s transformation: results from the phase II GIVeRS trial